Fulgent Genetics, Inc. (NASDAQ:FLGT) Shares Bought by Creative Planning

Creative Planning increased its holdings in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 55.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,924 shares of the company’s stock after purchasing an additional 6,415 shares during the period. Creative Planning owned 0.06% of Fulgent Genetics worth $352,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Millennium Management LLC raised its position in Fulgent Genetics by 34.3% during the 2nd quarter. Millennium Management LLC now owns 958,852 shares of the company’s stock worth $18,813,000 after buying an additional 244,981 shares during the last quarter. Divisadero Street Capital Management LP lifted its position in Fulgent Genetics by 46.4% in the second quarter. Divisadero Street Capital Management LP now owns 505,212 shares of the company’s stock valued at $9,912,000 after purchasing an additional 160,212 shares during the period. Bank of New York Mellon Corp boosted its holdings in Fulgent Genetics by 37.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 201,201 shares of the company’s stock valued at $3,948,000 after purchasing an additional 55,020 shares in the last quarter. Acadian Asset Management LLC increased its position in Fulgent Genetics by 593.5% during the 2nd quarter. Acadian Asset Management LLC now owns 62,724 shares of the company’s stock worth $1,227,000 after purchasing an additional 53,680 shares during the period. Finally, Acuitas Investments LLC purchased a new position in shares of Fulgent Genetics during the 2nd quarter worth approximately $962,000. 48.06% of the stock is owned by hedge funds and other institutional investors.

Fulgent Genetics Stock Performance

Shares of NASDAQ FLGT opened at $19.66 on Friday. The company’s fifty day moving average is $21.95 and its two-hundred day moving average is $21.49. The firm has a market capitalization of $588.31 million, a P/E ratio of -3.53 and a beta of 1.50. Fulgent Genetics, Inc. has a one year low of $18.91 and a one year high of $30.68.

Fulgent Genetics (NASDAQ:FLGT) last issued its earnings results on Friday, August 2nd. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.45. Fulgent Genetics had a negative net margin of 56.22% and a negative return on equity of 2.75%. The company had revenue of $71.03 million for the quarter, compared to analyst estimates of $69.07 million. During the same period in the prior year, the business posted ($0.33) earnings per share. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. On average, sell-side analysts forecast that Fulgent Genetics, Inc. will post -1.46 earnings per share for the current fiscal year.

Insider Activity

In other Fulgent Genetics news, CEO Ming Hsieh sold 2,313 shares of Fulgent Genetics stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total transaction of $52,805.79. Following the completion of the transaction, the chief executive officer now owns 707,275 shares in the company, valued at approximately $16,147,088.25. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 4,324 shares of company stock worth $98,717 over the last 90 days. 31.76% of the stock is currently owned by corporate insiders.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.